You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物(01877.HK)与华奥泰生物达成药品技术转让与合作开发
阿思达克 06-25 09:40

君实生物(01877.HK)公布,与华奥泰生物签署《药品技术转让与合作开发合同》。根据协议约定,公司同意以9,000万元人民币从华奥泰生物受让阿瓦斯汀单抗生物类似药(项目代号HOT1010)的现有研发成果及其後续技术支持。

在药品注册成功後,药品产生的全部营业利润按公司和华奥泰生物各50%的比例分配。HOT-1010是一款重组人源化抗血管内皮生长因子(VEGF)单克隆抗体注射液,已获得国家药监局核准签发的《药物临床试验批件》,处於临床试验I期阶段。HOT-1010 可以选择性地与人血管内皮生长因子(VEGF)结合并阻断其生物活性,主要用於治疗转移性结直肠癌和晚期、转移性或复发性非小细胞肺癌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account